Facebook Pixel Code

The Result of the Anti-Angiogenic Clinical Trial

This is a preview of the 20-page document
Read full text

Most of the anti-angiostatic drugs are still under the clinical trials and that is because of the condition of the trial itself and that include the safety, side effects, proper dosage and the best way to give the drug pill or injection. Apart from this a lot of ethical issues are also involved in it. Since for cancer therapy standard modes of treatment which are already FDA approved are in place so getting new modes of therapy launched is not an easy task and has to be covered properly from every aspect.

On the other hand, because of the problems that can be found during the trial such as difficulties with the production of the drugs or even the reproduction or the death of some patients under the trial. However, the result of the anti-angiogenic clinical trial is not always the desired result such as the treatment with endostatin did not promote significant tumour regression in neuroendocrine tumours (Lederman, 2001) and there is no survival advantages were demonstrated after treatment with Marimastat. In January 2007 researchers reported that there is no improvement in the survival rate of patients under trial with advanced pancreatic tumour treated with Avastin(Furchgott, 1990) as well a very new study In the 5th of December 2007 shows that the risks of using Avastin are more than its benefits in the treatment of the breast cancer.

A number of experimental models are available for the study of angiogenesis in normal (Funk, 1986., Passaniti 992)and tumour tissues (Ausprunk, 1975., Leunig 1992), but no model allows detailed assessment of the early phases of tumour-induced angiogenesis with simultaneous visualization of growth of micro tumours in vivo.

In a recent study, however, we used fluorescent intravital microscopy to develop a technique that allows noninvasive, in vivo and in situ monitoring of tumour angiogenesis and tumour growth in conscious mice (Tones, 1995). But this did not prevent the fact that anti-angiogenic can be an effective alternative drug to treat some kind of cancer better than the other established modalities with also with an acceptable set of side effects.

This is a preview of the 20-page document
Open full text
Close ✕
Tracy Smith Editor&Proofreader
Expert in: Health Sciences & Medicine, Medical science, Nursing
Hire an Editor
Matt Hamilton Writer
Expert in: Health Sciences & Medicine, Medical science, Nursing
Hire a Writer
preview essay on The Result of the Anti-Angiogenic Clinical Trial
We use cookies to create the best experience for you. Keep on browsing if you are OK with that, or find out how to manage cookies.
WE CAN HELP TO FIND AN ESSAYDidn't find an essay?

Please type your essay title, choose your document type, enter your email and we send you essay samples

Contact Us